Similar articles for PMID: 16529566

Year	Number of Results
2000	1
2001	1
2002	1
2003	8
2004	23
2005	18
2006	18
2007	18
2008	20
2009	6
2010	9
2011	9
2012	2
2013	9
2014	4
2017	1
2018	1
2024	0

1

Safety and tolerability of duloxetine in women with stress urinary incontinence.

Oelke M, Roovers JP, Michel MC. Oelke M, et al. BJOG. 2006 May;113 Suppl 1:22-6. doi: 10.1111/j.1471-0528.2006.00880.x. BJOG. 2006. PMID: 16529566 Review.

2

Duloxetine: a new approach for treating stress urinary incontinence.

Moore K. Moore K. Int J Gynaecol Obstet. 2004 Jul;86 Suppl 1:S53-62. doi: 10.1016/j.ijgo.2004.05.009. Int J Gynaecol Obstet. 2004. PMID: 15302567 Review.

3

Duloxetine for management of stress urinary incontinence.

Guay DR. Guay DR. Am J Geriatr Pharmacother. 2005 Mar;3(1):25-38. doi: 10.1016/j.amjopharm.2005.03.004. Am J Geriatr Pharmacother. 2005. PMID: 16089245 Review.

4

Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults.

Mariappan P, Ballantyne Z, N'Dow JM, Alhasso AA. Mariappan P, et al. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004742. doi: 10.1002/14651858.CD004742.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034945 Review.

5

The use of Duloxetine in the treatment of male stress urinary incontinence.

Fink KG, Huber J, Würnschimmel E, Schmeller NT. Fink KG, et al. Wien Med Wochenschr. 2008;158(3-4):116-8. doi: 10.1007/s10354-007-0494-7. Wien Med Wochenschr. 2008. PMID: 18330528 Clinical Trial.

6

Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial.

Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC; Duloxetine UI Study Group. Millard RJ, et al. BJU Int. 2004 Feb;93(3):311-8. doi: 10.1111/j.1464-410x.2004.04607.x. BJU Int. 2004. PMID: 14764128 Clinical Trial.

7

Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review.

Mariappan P, Alhasso A, Ballantyne Z, Grant A, N'Dow J. Mariappan P, et al. Eur Urol. 2007 Jan;51(1):67-74. doi: 10.1016/j.eururo.2006.08.041. Epub 2006 Sep 15. Eur Urol. 2007. PMID: 17014950 Review.

8

Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence.

Castro-Diaz D, Palma PC, Bouchard C, Haab F, Hampel C, Carone R, Zepeda Contreras S, Rodriguez Ginorio H, Voss S, Yalcin I, Bump RC; Duloxetine Dose Escalation Study Group. Castro-Diaz D, et al. Int Urogynecol J Pelvic Floor Dysfunct. 2007 Aug;18(8):919-29. doi: 10.1007/s00192-006-0256-x. Epub 2006 Dec 12. Int Urogynecol J Pelvic Floor Dysfunct. 2007. PMID: 17160693 Clinical Trial.

9

Tolerability of amine uptake inhibitors in urologic diseases.

Michel MC, Ruhe HG, de Groot AA, Castro R, Oelke M. Michel MC, et al. Curr Drug Saf. 2006 Jan;1(1):73-85. doi: 10.2174/157488606775252601. Curr Drug Saf. 2006. PMID: 18690917 Review.

10

An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.

Wernicke J, Lledó A, Raskin J, Kajdasz DK, Wang F. Wernicke J, et al. Drug Saf. 2007;30(5):437-55. doi: 10.2165/00002018-200730050-00007. Drug Saf. 2007. PMID: 17472422

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

139 results

Results by year